Anti-GLP-1 (7-37) and GLP-1 (7-36) amide (N-term) Antibody (10)
Our mouse GLP-1 (7-37) and GLP-1 (7-36) amide (N-term) monoclonal antibody from Antibodies Incorporated is produced in-house from clone 10. It detects human GLP-1 (7-37) and GLP-1 (7-36) amide (N-term) and is Protein A or Protein G purified. Works in ELISA, WB.
SKU: ABS 033-10-010
Ships: 1-2 business days
Product Details
GLP-1 (7-37) and GLP-1 (7-36) amide (N-term)
Glucagon-like peptide 1(7-36)amide (GLP-1(7-36)amide) is the principal active form of GLP-1, the other being GLP-1(7-37). GLP-1 is a peptide hormone of the glucagon family, produced by the L cells of the intestinal mucosa from the same prohormone as glucagon. The active forms are potent stimulators of glucose-dependent insulin secretion. The sequence of GLP-1 is fully conserved in all mammalian species examined so far.
Protein A or Protein G purified
1 mg/mL ±15%
Monoclonal
10
IgG2a/k
ELISA, WB
Mouse
GCG
20 kDa (proglucagon)
Synthetic GLP-1(7-17)
Human
Human
2-8°C without exposure to light
Liquid
BSA free
0.01 M phosphate buffer, pH 7.4, with 0.5 M NaCl and 15 mM sodium azide
ABS 033-10 binds free GLP-1(7-37) and free GLP-1(7-36)amide in solution. ABS 033-10 reacts in ELISA with GLP-1(7-37) coated directly onto the microtiter well. ABS 033-10 binds free exendin-4 in solution and can function as a capture antibody for exendin-4 in combination with ABS 012-35B in order to measure Exendin-4. ABS 046-03B as a biotinylated detection antibody and ABS 033-10 as a capture antibody can be used in sandwich ELISA.
Unconjugated
ABS 033-10 binds the free N-terminus of GLP-1(7-37) and GLP-1(7-36)amide and shows <0.2% cross-reactivity with GLP-1(9-36)amide, glucagon and human GIP. Cross-reacts 0.25% with GLP-1(1-37), approximately 6% with human GLP-2 and approximately 50% with exendin-4. ABS 033-10 cross-reacts with Liraglutide.
These antibodies are to be used as research laboratory reagents and are not for use as diagnostic or therapeutic reagents in humans.
United States
24 months from date of receipt
GCG; Pro-glucagon; Cleaved into: Glicentin; Glicentin-related polypeptide; GRPP; Oxyntomodulin; OXM; OXY; Glucagon; Glucagon-like peptide 1; GLP-1; Incretin hormone; Glucagon-like peptide 1(7-37; GLP-1(7-37; Glucagon-like peptide 1(7-36; GLP-1(7-36; Glucagon-like peptide 2; GLP-2; GLP1; GLP2; incretin; preproglucagon
[Glucagon]: Plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes. Binds to and activates the glucagon receptor GCGR, which couples to the G(s) G protein and elevates intracellular cAMP, triggering downstream metabolic responses (PubMed:32193322). {ECO:0000269|PubMed:32193322, ECO:0000303|PubMed:10605628, ECO:0000303|PubMed:12626323}.; [Glucagon-like peptide 1]: Potent stimulator of glucose-dependent insulin release (PubMed:22037645, PubMed:40446798). Also stimulates insulin release in response to IL6 (PubMed:22037645). Plays important roles on gastric motility and the suppression of plasma glucagon levels (PubMed:10605628, PubMed:14719035, PubMed:12554744). May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin (PubMed:10605628, PubMed:14719035, PubMed:12554744). Has growth-promoting activities on intestinal epithelium (PubMed:10605628, PubMed:14719035, PubMed:12554744). May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion (PubMed:10605628, PubMed:14719035, PubMed:12554744). Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferation (PubMed:10605628, PubMed:14719035, PubMed:12554744). Inhibits beta cell apoptosis (PubMed:10605628, PubMed:14719035, PubMed:12554744). {ECO:0000269|PubMed:22037645, ECO:0000269|PubMed:40446798, ECO:0000303|PubMed:10605628, ECO:0000303|PubMed:12554744, ECO:0000303|PubMed:14719035}.; [Glucagon-like peptide 2]: Stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability. {ECO:0000303|PubMed:10322410, ECO:0000303|PubMed:10605628, ECO:0000303|PubMed:12554744, ECO:0000303|PubMed:14719035}.; [Oxyntomodulin]: Significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension, which may contribute to satiety by causing a sensation of fullness. {ECO:0000303|PubMed:10605628, ECO:0000303|PubMed:12554744}.; [Glicentin]: May modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life. {ECO:0000303|PubMed:10605628, ECO:0000303|PubMed:12554744}.
2641
Shipped on ice packs

